Cytokeratin 8 Antibody (LP3K): sc-53266

Cytokeratin 8 Antibody (LP3K) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 8 in human samples through western blotting (WB) and immunoprecipitation (IP) applications. Cytokeratin 8 is a vital component of the cytoskeletal structure in epithelial cells, playing a crucial role in maintaining cellular integrity and providing mechanical support. Anti-Cytokeratin 8 antibody (LP3K) targets proteins predominantly located in the cytoplasm of simple epithelial cells, where Cytokeratin 8 forms intermediate filaments that contribute to the overall architecture of tissues. Cytokeratin 8 expression is particularly significant in epithelial differentiation and tissue specialization, as expression patterns often change in various malignancies. For instance, in squamous cell carcinomas derived from stratified epithelia, abnormal Cytokeratin 8 expression can be observed, which may indicate a shift in cellular phenotype associated with malignancy. Furthermore, Cytokeratin 8 expression has been identified as an independent prognostic marker in oral squamous cell carcinomas, correlating with poor patient outcomes. The ability of Cytokeratin 8 to present extracellular epitopes on tumor cells also highlights potential therapeutic targeting opportunities, making Cytokeratin 8 monoclonal antibody (LP3K) an essential tool for researchers investigating epithelial cell biology and cancer pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 8 Antibody (LP3K) References:

1. The possible role of cytokeratin 8 in cadmium-induced adaptation and carcinogenesis.  |  Lau, AT. and Chiu, JF. 2007. Cancer Res. 67: 2107-13. PMID: 17332340
2. Cytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization.  |  Wang, Y., et al. 2008. Cancer Lett. 265: 188-96. PMID: 18353540
3. Full-length cytokeratin 8 is released and circulates in patients with non-small cell lung cancer.  |  Ishii, T., et al. 2008. Tumour Biol. 29: 57-62. PMID: 18497550
4. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.  |  Obermajer, N., et al. 2009. Mol Cancer. 8: 88. PMID: 19845941
5. Cytokeratin 8 is expressed in human corneoconjunctival epithelium, particularly in limbal epithelial cells.  |  Merjava, S., et al. 2011. Invest Ophthalmol Vis Sci. 52: 787-94. PMID: 20926822
6. Use of cytokeratin 8 immunohistochemistry for assessing cell death after radiofrequency ablation of breast cancers.  |  Kreb, DL., et al. 2011. Biotech Histochem. 86: 404-12. PMID: 20950219
7. Cytokeratin 8 is increased in hepatitis C virus cells and its ectopic expression induces apoptosis of SMMC7721 cells.  |  Sun, MZ., et al. 2013. World J Gastroenterol. 19: 6178-87. PMID: 24115814
8. Cytokeratin 8-MHC class I interactions: a potential novel immune escape phenotype by a lymph node metastatic carcinoma cell line.  |  Wu, MS., et al. 2013. Biochem Biophys Res Commun. 441: 618-23. PMID: 24183726
9. Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.  |  Guo, D., et al. 2018. Int J Mol Sci. 19: PMID: 29443941
10. Knockdown of cytokeratin 8 overcomes chemoresistance of chordoma cells by aggravating endoplasmic reticulum stress through PERK/eIF2α arm of unfolded protein response and blocking autophagy.  |  Wang, D., et al. 2019. Cell Death Dis. 10: 887. PMID: 31767864

The preferred Cytokeratin 8 antibody is Cytokeratin 8 Antibody (C51): sc-8020.